Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022

Horiba Medical (Kyoto, Japan) showcased its hematology and hemostasis solutions at the EUROMEDLAB 2022 which took place from April 10 to 14 at the ICM Internationales Congress Center, Munich, Germany. More...

The company also presented scientific posters on its high range hematology solutions during the poster session time.

At its exhibition booth, Horiba showcased its automation high-end HELO Global Hematology Solution covering all the needs of a high throughput automated hematology platform. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses all the needs of laboratories, but helps to optimize their TAT, floor space and reagent storage. Among its Yumizen range of hematology solutions, Horiba displayed its Yumizen H2500/H1500 and the Yumizen H550 hematology analyzers. The Yumizen H2500/H1500 has a real throughput of 120 samples per hour for CBC-DIFF NRBC and slides and come with on board reagents (5 for Yumizen H2500 and 4 for Yumizen H1500). Along with testing for up to 55 parameters, their automatic 360°C rotative sample mixing provides perfect homogeneity. On the other hand, the Yumizen H550 is a compact 6-diff hematology analyzer with an auto sampling system which aims at providing a full walk away capability to a variety of clinical environments: hospitals, satellite labs, emergency care, small independent labs, and doctors’ offices.

Among its Yumizen range of hemostasis solutions, Horiba displayed its Yumizen G1550/G1500 and Yumizen G400 hemostasis analyzers. The Yumizen G1550/G1500 automated analyzer offers routine and specialized testing in a single analysis system along with liquid and ready-to-use reagents for 80% of laboratory activity. It offers up to eight measuring channels with two wavelength combinations, continuous loading, and simplified anteriority management thanks to a large database of 1,000,000 results. The Yumizen G400 semi-automated hemostasis analyzer offers four independent measuring channels and 20 incubation positions and is easy to operate with an innovative user interface. Other solutions on display at the Horiba EUROMEDLAB 2022 exhibition booth included the Yumizen SPS slide maker, the CellaVision DC-1 digital cell morphology system, the Yumizen P8000 middleware and expert validation station and the Yumizen T6000 automated conveyor.

Related Links:
Horiba Medical 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.